Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313492 | 1.00 | TLR8 (0.36) | TLR8AR | |
| SCHEMBL25904920 | 0.88 | PDK2 (0.34) | TLR8AR | |
| SCHEMBL25938341 | 0.84 | TLR8 (0.41) | TLR8 | |
| SCHEMBL25314887 | 0.80 | TLR8 (0.38) | TLR8AR | |
| SCHEMBL25923351 | 0.80 | TLR8 (0.38) | TLR8AR | |
| SCHEMBL26022451 | 0.80 | TLR8 (0.34) | TLR8AR | |
| SCHEMBL25316918 | 0.79 | AR (0.40) | TLR8AR | |
| SCHEMBL25923353 | 0.79 | AR (0.40) | TLR8AR | |
| SCHEMBL31436563 | 0.78 | AR (0.35) | AR | |
| SCHEMBL31349573 | 0.78 | AR (0.32) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | TLR8 4267/4885AR 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.